Startseite › Multiples Myelom › Utah › Salt Lake City
Klinische Studien zu Multiples Myelom in Salt Lake City, UT
21 Studien zu Multiples Myelom suchen Teilnehmer an Standorten in und um Salt Lake City (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Teilnehmer gesuchtPhase 3
- Research Site, Salt Lake City
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Teilnehmer gesuchtPhase 1/2
- Huntsman Cancer Institute, Salt Lake City
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 3
- Utah Cancer Specialists, Salt Lake City
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 3
- Huntsman Cancer Institute, Salt Lake City
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Teilnehmer gesuchtPhase 3
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, Salt Lake City
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Teilnehmer gesuchtPhase 3
- LDS Hospital, Salt Lake City
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Teilnehmer gesuchtPhase 2
- Intermountain Healthcare, Salt Lake City
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Teilnehmer gesuchtPhase 3
- Huntsman Cancer Institute, Salt Lake City
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 2
- LDS Hospital, Salt Lake City
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Teilnehmer gesuchtPhase 1/2
- Huntsman Cancer Institute /ID# 271618, Salt Lake City
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Teilnehmer gesuchtPhase 2
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
Teilnehmer gesuchtPhase 2
- Huntsman Cancer Institute, Salt Lake City
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Teilnehmer gesuchtPhase 1/2
- Research Site, Salt Lake City
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Teilnehmer gesuchtPhase 1
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Teilnehmer gesuchtPhase 1/2
- Huntsman Cancer Institute /ID# 272575, Salt Lake City
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
Teilnehmer gesuchtPhase 2
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1
- Huntsman Cancer Center Institute University of Utah, Salt Lake City
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Teilnehmer gesuchtPhase 1
- University of Utah, Salt Lake City
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Teilnehmer gesuchtPhase 1/2
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Teilnehmer gesuchtBeobachtungsstudie
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Multiples Myelom-Studien in anderen Städten
- New York City, NY60 Studien
- Boston, MA42 Studien
- Atlanta, GA41 Studien
- Houston, TX38 Studien
- Durham, NC37 Studien
- Nashville, TN32 Studien
- Denver, CO27 Studien
- Rochester, MN24 Studien
- St. Louis, MO24 Studien
- Columbus, OH24 Studien
- Baldwin Park, CA23 Studien
- Chicago, IL22 Studien
Weitere Studien in Salt Lake City
- Nichtkleinzelliges Lungenkarzinom31 Studien
- Krebs (alle Arten)27 Studien
- Brustkrebs27 Studien
- Kolorektales Karzinom21 Studien
- Lungenkrebs21 Studien
- Melanom21 Studien
- Metastasierender Krebs20 Studien
- Eierstockkrebs19 Studien
- Adipositas18 Studien
- Akute myeloische Leukämie17 Studien
- Herzinsuffizienz17 Studien
- Prostatakrebs15 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 05.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.